JUNS - Jupiter Neurosciences, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

JUNS

JUPITER NEUROSCIENCES, INC.

NASDAQ

$4.18

▼ DOWN 14.52% (-0.71)

KEY STATISTICS

Market Cap$2.03 M

52w High$138.00

52w Low$4.10

Dividend Yield—

Frequency—

P/E-15.48

Volume204.25K

Shares Out.484.67K

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Christer Rosen

COMPENSATION 2026

Salary$441,000

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$20,407

Total$671,407

ABOUT

SECTOR

Healthcare

WENT PUBLIC

December 3, 2024

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateDec 2, 2026

DayWednesday

Rev. Est.$602.00K

DEC

WED

SPLIT RECORD

DATE	TYPE	RATIO
2026-08-07	Reverse	1:75

PRICE

$4.18 ▼ DOWN 14.52% (−$0.71)

OVERLAYS

About Jupiter Neurosciences, Inc.

https://jupiterneurosciences.com ↗

Jupiter Neurosciences, Inc. is a clinical-stage biotech developing resveratrol-based therapies for neuro-inflammation and neurological disorders, with multiple Phase II trials for conditions like Friedreich's Ataxia, Alzheimer's, MPS I, MELAS, ALS...

INDUSTRY

Biotechnology

A PRODUCT JUPITER NEUROSCIENCES, INC. IS KNOWN FOR

Nugevia™

A direct-to-consumer line of performance and longevity supplements using Jupiter Neurosciences' proprietary JOTROL™ resveratrol platform, focusing on mitochondrial support, mental clarity, and beauty-from-within for the wellness market.